Furthermore, we demonstrated the efficacy of anti‐IL‐17RA mAb in a murine model of SSc, suggesting that Brodalumab treatment is a novel and promising strategy for improving the outcomes of patients with SSc. The gene discussed is IL17RA; the disease is systemic sclerosis.